Evogene Ltd. (EVGN)
1.52
-0.03 (-1.94%)
At close: Jan 14, 2025, 3:48 PM
1.52
0.00%
After-hours Jan 14, 2025, 03:48 PM EST
undefined% (undefined)
| Bid | 1.5 |
| Market Cap | 8.16M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.4 |
| PE Ratio (ttm) | -0.35 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.57 |
| Volume | 13,925 |
| Avg. Volume (20D) | 308,659 |
| Open | 1.58 |
| Previous Close | 1.55 |
| Day's Range | 1.50 - 1.61 |
| 52-Week Range | 1.20 - 10.40 |
| Beta | undefined |
About EVGN
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2010
Employees 142
Stock Exchange NASDAQ
Ticker Symbol EVGN
Website https://www.evogene.com
Analyst Forecast
According to 1 analyst ratings, the average rating for EVGN stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 689.47% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Evogene Ltd. is scheduled to release its earnings on Mar 6, 2025,
before market opens.
Analysts project revenue of $3.62M, reflecting a 526.30% YoY growth and earnings per share of -0.73, making a -43.85% decrease YoY.
Analysts project revenue of $3.62M, reflecting a 526.30% YoY growth and earnings per share of -0.73, making a -43.85% decrease YoY.
3 months ago ·
Source
+19.92%
Evogene shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago ·
Source
-10.8%
Evogene shares are trading lower after the company reported worse-than-expected Q2 EPS results.
